title: Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes.
abstract: Disordered glucose metabolism is a common complication of glucocorticoid therapy for acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation (HCT). We aimed to examine the impact of dysglycemia on outcomes in 173 recipients of HCT treated with glucocorticoids for aGVHD. A total of 147 of these patients contributed data to a landmark analysis performed at 12 weeks post-HCT. Median aGVHD onset was 21 days (range: 5-79) after transplant. Median duration of glucocorticoid therapy was 381 days (range: 15-1632). Glucose values were obtained from glucocorticoid initiation date to death or last follow-up, resulting in 11,588 total values. The median (range) for each parameter were: maximum 292 mg/dL (128-694), minimum 75 mg/dL (34-142), average 142 mg/dL (86-327), and standard deviation 46 mg/dL (12-108). Baseline diabetes mellitus predicted significantly greater maximum, mean, and standard deviation. With median follow-up of 20 months (range: 3-55), median overall survival (OS) was 33.7 months (95% confidence interval [CI] 16.4-not reached). On multivariable analysis, maximum, average, or standard deviation of glucose values predicted OS and maximum or average glucose values predicted nonrelapse mortality (NRM). Minimum glucose values of (0-60 mg/dL) were associated with worsened OS and increased NRM. Those patients treated with insulin or oral agents suffered significantly worse OS and increased NRM compared to patients who did not need therapy. Finally, those with sustained maximum values >200 mg/dL despite treatment suffered worse OS and increased NRM. These data suggest an independent adverse effect of dysglycemia in patients treated with glucocorticoids for aGVHD, and argue for stringent glycemic control in this setting.
authors.affiliation: Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, Florida, USA. joseph.pidala@moffitt.org
authors.forename: Joseph
authors.initials: J
authors.lastname: Pidala
authors.forename: Jongphil
authors.initials: J
authors.lastname: Kim
authors.forename: Mohamed A
authors.initials: MA
authors.lastname: Kharfan-Dabaja
authors.forename: Taiga
authors.initials: T
authors.lastname: Nishihori
authors.forename: Teresa
authors.initials: T
authors.lastname: Field
authors.forename: Janelle
authors.initials: J
authors.lastname: Perkins
authors.forename: Lia
authors.initials: L
authors.lastname: Perez
authors.forename: Hugo
authors.initials: H
authors.lastname: Fernandez
authors.forename: Claudio
authors.initials: C
authors.lastname: Anasetti
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D015331:Cohort Studies; D048909:Diabetes Complications; D016903:Drug Monitoring; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects* / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000097:blood* / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced*; D007003:Hypoglycemia / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001786:Blood Glucose; D005938:Glucocorticoids; D011241:Prednisone